Last reviewed · How we verify
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Nicotinamide, ABA and Zinc PCA | Nicotinamide, ABA and Zinc PCA | marketed | ||||
| Triamcinolone Acetonide (TA) | Triamcinolone Acetonide (TA) | marketed | Corticosteroid (glucocorticoid) | Glucocorticoid receptor | Immunology, Dermatology, Rheumatology, Ophthalmology |
Therapeutic area mix
- Immunology, Dermatology, Rheumatology, Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Benazir Bhutto Hospital, Rawalpindi · 1 shared drug class
- Berinstein, Jeffrey · 1 shared drug class
- Celgene · 1 shared drug class
- Children's Hospital of Philadelphia · 1 shared drug class
- Chong Kun Dang Pharmaceutical · 1 shared drug class
- Ain Shams University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Rumah Sakit Pusat Angkatan Darat Gatot Soebroto:
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto pipeline updates — RSS
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto pipeline updates — Atom
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rumah Sakit Pusat Angkatan Darat Gatot Soebroto — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rumah-sakit-pusat-angkatan-darat-gatot-soebroto. Accessed 2026-05-17.